AQuify Multi-Purpose Solution is indicated for cleaning, rinsing, chemical (not heat) disinfecting, storing for soft (hydrophilic) lenses (including silicone hydrogel lenses) as recommended by your eye care practitioner. AQuify Multi-Purpose Solution is also indicated for taily protein removal of lenses replaced in 30 days or less.

Device Description

AQuify Multi-Purpose Solution is a sterile aqueous solution containing sorbitol, tromethamine, pluronic F127, sodium phosphate dihydrogren, dexpanthnol, edetate disodium dihydrate and preserved with polyhexanide 0.0001.

AI/ML Overview

The provided text describes the 510(k) summary for the Aquify Multi-Purpose Solution (K033608). It references prior studies submitted under K021635 to demonstrate substantial equivalence to currently marketed products.

Here's an analysis of the acceptance criteria and study information, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document speaks to general efficacy and safety rather than explicit, quantified acceptance criteria with specific thresholds for "performance." However, it states that the product met both the secondary stand alone criteria and the regimen test criteria for disinfection efficacy and that Results showed that AQuify MPS is substantially equivalent to currently marketed products in terms of daily protein removal.

Acceptance Criteria (Implied)	Reported Device Performance
Substantial equivalence to predicate for cleaning, rinsing, chemical (not heat) disinfecting, storing, and daily protein removal.	`AQuify MPS is substantially equivalent to currently marketed products in terms of daily protein removal.` and `The data provided...concludes that AQuify Multi-Purpose Solution is substantially equivalent to currently cleared KARATS Multi-Purpose Solution` for all indicated uses.
Non-toxicity and biocompatibility.	`Results demonstrate the solution is non-toxic and biocompatible, and is comparable to other currently marketed soft contact lens solutions.`
Non-cytotoxicity and non-irritancy.	`Results of the testing demonstrated that AQuify MPS is non-cytotoxic and is a non-irritant.`
Microbiological efficacy (disinfection).	`met both the secondary stand alone criteria and the regimen test criteria for disinfection efficacy.`

2. Sample Size Used for the Test Set and Data Provenance

Test Set Sample Size: Not explicitly stated in K033608. The document refers to studies previously submitted under K021635, which would contain this detail.
Data Provenance: Not explicitly stated in K033608. The studies were conducted by CIBA Vision Corporation. It's common for such studies to be conducted internally or by contract research organizations, but specific country of origin or retrospective/prospective nature is not detailed here. It refers to "clinical studies" implying prospective testing, but without further detail.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

This information is not provided in the document. The studies are in vitro (microbiological, cleaning, cytotoxicity) and clinical. For in vitro studies, "ground truth" would be objective measurements. For clinical studies, the "ground truth" would relate to patient outcomes or physiological assessments, typically by eye care professionals, but the number and qualifications are not listed.

4. Adjudication Method for the Test Set

This information is not provided in the document, as the studies are not described in this level of detail. Such methods are more relevant for subjective assessments, which are not explicitly detailed here.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance

This is not applicable. The device is a multi-purpose contact lens solution, not an AI-powered diagnostic or assistive tool for human readers. Therefore, an MRMC study and AI assistance effect size are not relevant to this submission.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

This is not applicable for a contact lens solution. However, the secondary stand alone criteria for microbiological efficacy can be interpreted as a standalone performance test for the solution's disinfectant properties, independent of a full regimen (which usually involves user handling). This refers to the solution's inherent killing power in a laboratory setting.

7. The Type of Ground Truth Used

For in vitro studies (cleaning efficacy, enzyme compatibility, cytotoxicity, microbiological efficacy): The ground truth would be based on objective laboratory measurements, standardized testing protocols (e.g., ISO or FDA/ASTM standards for disinfection), and established scientific methods.
For clinical studies: The ground truth would likely be clinical endpoints related to ocular health, comfort, adverse events, and lens performance as assessed by eye care practitioners and patient feedback.

8. The Sample Size for the Training Set

This is not applicable, as the Aquify Multi-Purpose Solution is a chemical solution, not a machine learning or AI-based device that requires a "training set."

9. How the Ground Truth for the Training Set Was Established

Not applicable for the same reason as point 8.

Summary

{0}------------------------------------------------

K033608

PART IX. 510(k) SUMMARY

FEB = 2 2004

In response to the requirements addressed by the Safe Medical Devices Act (SMDA) of 1990, a summary follows with the safety and effectiveness information upon which the substantial equivalence determination is based.

510(k) SUMMARY for Aquify Multi-Purpose Solution

1. Submitter Information

CIBA Vision Corporation 11460 Johns Creek Parkway Duluth, Georgia 30097 Contact Person: Telephone No.

Steven Dowdley 678-415-3897

2. Device Name

Classification Name: Proprietary Name:

Soft (hydrophilic) Contact Lens Solution AQUIFY Multi-purpose Solution

3. Predicate Device(s)

AQuify Multi-purpose Solution (KARATS Multi-purpose Solution) - K 021635

4. Description of the Device

5. Indications for Use

Description of Safety and Substantial Equivalence 6.

A series of preclinical and clinical studies have been completed on this product and were previously submitted under submission K021635. The non-clinical and clinical studies were completed to demonstrate the substantial equivalence of AQUIFY MPS to other currently marketed solutions. All testing was conducted in accordance with and in conformance to applicable device regulations. Results demonstrate the solution is non-toxic and biocompatible, and is comparable to other currently marketed soft contact lens solutions.

In Vitro Cleaning Efficacy

Results of the study showed that AQuify MPS is substantially equivalent to currently marketed products in terms of daily protein removal. This data was previously submitted and reviewed in original 510(k) submission - K021635.

Enzyme Compatibility

The study was conducted to evaluate the proteolytic activity of Unizyme tablets in AQuify MPS (KARATS - 257), SOLOcare Plus and ReNu Multiplus lens care solutions. The results demonstrated that Unizyme tablets dissolved in either AQuify MPS was substantially equivalent to other multi-purpose solution when used as a diluents.

{1}------------------------------------------------

Cytotoxicity

A series of cytotoxicity studies were previously conducted to demonstrate the safety of AQuify MPS. Results of the testing demonstrated that AQuify MPS is non-cytotoxic and is a non-irritant. This data was previously submitted and reviewed in original 510(k) submission - K021635.

Microbiological

Two series of microbiological studies were conducted to demonstrate the microbial efficacy AQuify Multi-Purpose Solution. For the regimen evaluated, the product met both the secondary stand alone criteria and the regimen test criteria for disinfection efficacy.

Clinical Testing

A series of clinical studies have been conducted, submitted and reviewed in 510(k) submission K021635. Data from the clinical studies supported the substantial equivalence of AQuily Multi-Purpose Solution.

7. Substantial Equivalence

The data provided in this 510(k) submission concludes that AQuify Multi-Purpose Solution is substantially equivalent to currently cleared KARATS Multi-Purpose Solution for cleaning, rinsing, chemical (not heat) disinfecting, storing and daily protein removal (when used for lenses replace in and storing soft (hydrophilic) lenses (including silicone hydrogel lenses) as recommended by your eve care practitioner.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus symbol.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

CIBA Vision Corporation c/o Steven Dowdley 11460 Johns Creck Pkwy. Duluth. GA 30097

FEB - 2 2004

Re: K033608

Trade/Device Name: AQuify Multi-Purpose Solution Regulation Number: 21 CFR 886.5928 Regulation Name: Soft (hydrophilic) contact lens care Regulatory Class: Class II Product Code: LPN Dated: January 6, 2004 Received: January 7, 2004

Dear Mr. Dowdley:

We have reviewed your Scction 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as sct forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 - Steven Dowdley

This letter will allow you to begin marketing your device as described in your Section 510/k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

A Ralph Rosenthal

A. Ralph Rosenthal, M.D. Dircctor Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

PART 111. INDICATIONS FOR USE STATEMENT

510(k) Number: (Number to be assigned) |< 0 3 3 60 8

Device Name: AQuify Multi-Purpose Solution

Indications for Use:

indications for Use:
AQuily Multi-Purpose Solution is indicated for cleaning, rinsing, chemical (not heat) disintecting, storing for AQuily Multi-Purpose Solution is indication for dealing, moment (ded by your eye care soft (hydrophile) lenses (including silcone hydrogenentood by protein removal of lenses replaced in 30 days or less.

Concurrence of CDRH, Office of Device Evaluation (ODE)
--------------------------------------------------------	--

Prescription Use:	or over-the-counter:
(Division Sign-Off)
Division of Ophthalmic Ear, Nose and Throat Devises
510(k) Number	K033608

Regulation Number and Section

§ 886.5928 Soft (hydrophilic) contact lens care products.

(a)
Identification. A soft (hydrophilic) contact lens care product is a device intended for use in the cleaning, rinsing, disinfecting, lubricating/rewetting, or storing of a soft (hydrophilic) contact lens. This includes all solutions and tablets used together with soft (hydrophilic) contact lenses and heat disinfecting units intended to disinfect a soft (hydrophilic) contact lens by means of heat.(b)
Classification. Class II (Special Controls) Guidance Document: “Guidance for Industry Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products.”